bYoRNA
June 19, 2025
Company Presentation
Platform for Therapeutics
153A
bYoRNA is a biotech platform specializing in the production of therapeutic mRNA using recombinant yeast. Yeast can produce long mRNA (up to 14,000 nucleotides) ideal for gene editing and cell reprogramming, with lower immunogenicity (no immunogenic dsRNA) and higher integrity (low-modified bases so no frameshifting). This will improve the efficiency of mRNA drugs and their approval rate by regulation authorities, while allowing for local, scalable, and crisis-proof production.
We have a worldwide license to an US/EU patent from the CNRS and U. of Orleans. We have partnered with TRON, the German mRNA research institute created by the founders of BioNTech and are currently negotiating deal agreements with a large pharma and a rare disease research institute.
Founders include Chantal Pichon (the patent inventor and a Professor at INSERM and Charité Berlin), Thierry Ziegler (a 25-year bioproduction C-level executive) and Pascal Viguié (a high tech entrepreneur with a 40m USD past exit).
Company HQ City:
Bordeaux-Pessac
Company HQ State:
Nouvelle Aquitaine
Company HQ Country:
France
Year Founded:
2022
Lead Product in Development:
mRNA bioproduction platform (longer mRNA without dsRNA nor frameshifting)
CEO
Pascal Viguié
Development Phase of Lead Product
Other/Not Applicable
Number of Unlicensed Products Looking for Licensing
N/A
When you expect your next catalyst update?
Animal PoC
What is your next catalyst (value inflection) update?
December 2025
Website
www.byorna.bio
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}